International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1329-1337 , 1 August 2010

Causes of Death in Men With Prevalent Diabetes and Newly Diagnosed High- Versus Favorable-Risk Prostate Cancer

  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, MA
    • Corresponding Author InformationReprint requests to: Anthony V. D'Amico, M.D., Ph.D., Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis St., L-2 Level, Boston, MA 02215. Tel: (617) 632-6328; Fax: (617) 632-216
    • ,
  • Michelle H. Braccioforte, B.S.

      Affiliations

    • Department of Radiation Oncology, Prostate Cancer Foundation of Chicago, Westmont, IL
    • ,
  • Brian J. Moran, M.D.

      Affiliations

    • Department of Radiation Oncology, Prostate Cancer Foundation of Chicago, Westmont, IL
    • ,
  • Ming-Hui Chen, Ph.D.

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, CT

Received 21 April 2009 ,Revised 25 June 2009 ,Accepted 26 June 2009.

References 

  1. Walsh PC, DeWeese TL, Eisenberger MA. Clinical practice: Localized prostate cancer. N Engl J Med. 2007;357:2696–2705
  2. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  3. Merrick GS, Galbreath RW, Butler WM, et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer. 2007;110:289–296
  4. Park SM, Lim MK, Shin SA, et al. Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation study. J Clin Oncol. 2006;24:5017–5024
  5. van de Poll-Franse LV, Houterman S, Jannssen-Heijnen ML, et al. Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis. Int J Cancer. 2007;120:1986–1992
  6. Smith MR, Bae K, Efstathiou JA, et al. Diabetes and mortality in men with locally advanced prostate cancer: RTOG 9202. J Clin Oncol. 2008;26:4333–4339
  7. Barone BB, Yeh Hsin-Chieh Y, Synder CF, et al. Long-term all cause mortality in cancer patients with preexisting diabetes mellitus. JAMA. 2008;300:2754–2764
  8. Greene FL. Prostate. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002;p. 309–316
  9. Cooperberg MR, Cowan J, Broering JM, et al. High-risk prostate cancer in the United States, 1990–2007. World J Urol. 2008;26:211–218
  10. D'Amico, AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer following brachytherapy alone or with radiation, androgen suppression therapy or both in men with high-risk disease. J Clin Oncol. Electronic publication July 13, 2009.
  11. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–4456
  12. In:  Agresti A editors. An Introduction to Categorical Data Analysis. 2nd ed. New York: John Wiley & Sons; 2002;p. 16–52
  13. In:  Hollander M,  Wolfe DA editor. Nonparametric Statistical Methods. 2nd ed. New York: John Wiley & Sons; 1999;p. 189–269
  14. In:  Agresti A editors. An Introduction to Categorical Data Analysis. 2nd ed. New York: John Wiley & Sons; 2002;p. 165–210
  15. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  16. Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  17. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In:  Klein JP,  Moeschberger ML editor. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York: Springer; 2003;p. 243–293
  18. Lee WR, deGuzman AF, Bare RL, et al. Postbrachytherapy analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys. 2000;46:83–88
  19. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data. J Am Stat Assoc. 1993;88:400–409
  20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  21. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–500
  22. In:  Neter J,  Wassermann W,  Kutner M editor. Simultaneous inferences and other topics in regression analyses-1. In: Applied Linear Regression Models. Homewood, IL: Richard D Irwin; 1983;p. 150–153
  23. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: A population-based cohort study. Diabetes Care. 2008;31:1761–1766
  24. Available from: www.cancer.org/docroot/cri/content/cri_2_4_3x_can_prostate_cancer_be_found_early_36.asp. Accessed January 15, 2009.
  25. Catalona WJ. Management of prostate cancer. N Engl J Med. 1994;331:996–1004
  26. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(Suppl.):5060
  27. Bolla M, van Poppel H, Collette L, et al. European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911). Lancet. 2005;366:572–578
  28. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol. 2009;181:956–962
  29. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external bean radiotherapy for locally advanced prostate cancer; Long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591
  30. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285–1290
  31. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 9202. J Clin Oncol. 2003;21:3972–3978
  32. Denham J, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96-01 randomised controlled trial. Lancet Oncol. 2005;6:841–850
  33. D'Amico AV, Chen M, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA. 2008;299:289–295
  34. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433–439

 Conflict of interest: none.

PII: S0360-3016(09)01002-5

doi: 10.1016/j.ijrobp.2009.06.051

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1329-1337 , 1 August 2010

Article Tools

* Image Usage & Resolution